10 20 30 40 50 60 70 80 2C17 - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER OXIDOREDUCTASE 02-JUN-99 2C17
TITLE COMPUTATIONAL MODEL OF HUMAN P450C17
COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEIN (CYTOCHROME P450 XVIIA1); COMPND 3 CHAIN: A; COMPND 4 SYNONYM: P450-C17, STEROID 17-ALPHA-HYDROXYLASE, 17/20- COMPND 5 LYASE; COMPND 6 EC: 1.14.99.9
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN
KEYWDS 17-ALPHA-HYDROXYLASE, 17/20-LYASE, P450C17, SEX STEROID KEYWDS 2 BIOSYNTHESIS, OXIDOREDUCTASE
EXPDTA THEORETICAL MODEL
AUTHOR R.J.AUCHUS,W.L.MILLER
REVDAT 3 01-APR-03 2C17 1 JRNL REVDAT 2 26-SEP-01 2C17 3 ATOM LINK CONECT REVDAT 1 19-JUL-99 2C17 0
JRNL AUTH R.J.AUCHUS,W.L.MILLER JRNL TITL MOLECULAR MODELING OF HUMAN P450C17 JRNL TITL 2 (17ALPHA-HYDROXYLASE/17,20-LYASE): INSIGHTS INTO JRNL TITL 3 REACTION MECHANISMS AND EFFECTS OF MUTATIONS. JRNL REF MOL.ENDOCRINOL. V. 13 1169 1999 JRNL REFN ASTM MOENEN US ISSN 0888-8809
REMARK 1
REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : NULL REMARK 3 AUTHORS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: MIDASPLUS GRAPHICS PLUS AMBER REMARK 3 MINIMIZATION/DYNAMICS. DETAILS IN MOL ENDO REFERENCE.
REMARK 4 REMARK 4 2C17 COMPLIES WITH FORMAT V. 2.3, 09-JULY-1998
REMARK 7 REMARK 7 COMPUTER MODEL BASED ON P450BMP TEMPLATE.
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 07-JUN-1999. REMARK 100 THE RCSB ID CODE IS RCSB001146.
REMARK 220 REMARK 220 EXPERIMENTAL DETAILS REMARK 220 EXPERIMENT TYPE : THEORETICAL MODELLING REMARK 220 REMARK 220 REMARK: NULL
REMARK 225 REMARK 225 THEORETICAL MODEL REMARK 225 THE COORDINATES IN THIS ENTRY REPRESENT A MODEL STRUCTURE. REMARK 225 PROTEIN DATA BANK CONVENTIONS REQUIRE THAT CRYST1 AND REMARK 225 SCALE RECORDS BE INCLUDED, BUT THE VALUES ON THESE REMARK 225 RECORDS ARE MEANINGLESS.
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 114 123.22 66.99 REMARK 500 LEU A 170 -35.32 59.38 REMARK 500 ILE A 334 -91.09 55.28 REMARK 500 HIS A 360 -57.91 59.81 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ARG A 49 PRO A 50 143.83 REMARK 500 ARG A 302 LEU A 303 -33.64 REMARK 500 ASP A 331 SER A 332 -126.90 REMARK 500 SER A 380 PRO A 381 -142.72
REMARK 650 REMARK 650 HELIX REMARK 650 DETERMINATION METHOD: AUTHOR DETERMINED
REMARK 700 REMARK 700 SHEET REMARK 700 DETERMINATION METHOD: AUTHOR DETERMINED
REMARK 999 REMARK 999 SEQUENCE REMARK 999 MODEL CONSTRUCTED WITH RESIDUES 1-454; REMARK 999 FROM A-HELIX TO LAST OBSERVED RESIDUE IN P450BMP X-RAY REMARK 999 STRUCTURE
DBREF 2C17 A 1 454 UNP P05093 CPT7_HUMAN 48 501
SEQRES 1 A 454 HIS MET HIS ASN ASN PHE PHE LYS LEU GLN LYS LYS TYR SEQRES 2 A 454 GLY PRO ILE TYR SER VAL ARG MET GLY THR LYS THR THR SEQRES 3 A 454 VAL ILE VAL GLY HIS HIS GLN LEU ALA LYS GLU VAL LEU SEQRES 4 A 454 ILE LYS LYS GLY LYS ASP PHE SER GLY ARG PRO GLN MET SEQRES 5 A 454 ALA THR LEU ASP ILE ALA SER ASN ASN ARG LYS GLY ILE SEQRES 6 A 454 ALA PHE ALA ASP SER GLY ALA HIS TRP GLN LEU HIS ARG SEQRES 7 A 454 ARG LEU ALA MET ALA THR PHE ALA LEU PHE LYS ASP GLY SEQRES 8 A 454 ASP GLN LYS LEU GLU LYS ILE ILE CYS GLN GLU ILE SER SEQRES 9 A 454 THR LEU CYS ASP MET LEU ALA THR HIS ASN GLY GLN SER SEQRES 10 A 454 ILE ASP ILE SER PHE PRO VAL PHE VAL ALA VAL THR ASN SEQRES 11 A 454 VAL ILE SER LEU ILE CYS PHE ASN THR SER TYR LYS ASN SEQRES 12 A 454 GLY ASP PRO GLU LEU ASN VAL ILE GLN ASN TYR ASN GLU SEQRES 13 A 454 GLY ILE ILE ASP ASN LEU SER LYS ASP SER LEU VAL ASP SEQRES 14 A 454 LEU VAL PRO TRP LEU LYS ILE PHE PRO ASN LYS THR LEU SEQRES 15 A 454 GLU LYS LEU LYS SER HIS VAL LYS ILE ARG ASN ASP LEU SEQRES 16 A 454 LEU ASN LYS ILE LEU GLU ASN TYR LYS GLU LYS PHE ARG SEQRES 17 A 454 SER ASP SER ILE THR ASN MET LEU ASP THR LEU MET GLN SEQRES 18 A 454 ALA LYS MET ASN SER ASP ASN GLY ASN ALA GLY PRO ASP SEQRES 19 A 454 GLN ASP SER GLU LEU LEU SER ASP ASN HIS ILE LEU THR SEQRES 20 A 454 THR ILE GLY ASP ILE PHE GLY ALA GLY VAL GLU THR THR SEQRES 21 A 454 THR SER VAL VAL LYS TRP THR LEU ALA PHE LEU LEU HIS SEQRES 22 A 454 ASN PRO GLN VAL LYS LYS LYS LEU TYR GLU GLU ILE ASP SEQRES 23 A 454 GLN ASN VAL GLY PHE SER ARG THR PRO THR ILE SER ASP SEQRES 24 A 454 ARG ASN ARG LEU LEU LEU LEU GLU ALA THR ILE ARG GLU SEQRES 25 A 454 VAL LEU ARG LEU ARG PRO VAL ALA PRO MET LEU ILE PRO SEQRES 26 A 454 HIS LYS ALA ASN VAL ASP SER SER ILE GLY GLU PHE ALA SEQRES 27 A 454 VAL ASP LYS GLY THR GLU VAL ILE ILE ASN LEU TRP ALA SEQRES 28 A 454 LEU HIS HIS ASN GLU LYS GLU TRP HIS GLN PRO ASP GLN SEQRES 29 A 454 PHE MET PRO GLU ARG PHE LEU ASN PRO ALA GLY THR GLN SEQRES 30 A 454 LEU ILE SER PRO SER VAL SER TYR LEU PRO PHE GLY ALA SEQRES 31 A 454 GLY PRO ARG SER CYS ILE GLY GLU ILE LEU ALA ARG GLN SEQRES 32 A 454 GLU LEU PHE LEU ILE MET ALA TRP LEU LEU GLN ARG PHE SEQRES 33 A 454 ASP LEU GLU VAL PRO ASP ASP GLY GLN LEU PRO SER LEU SEQRES 34 A 454 GLU GLY ILE PRO LYS VAL VAL PHE LEU ILE ASP SER PHE SEQRES 35 A 454 LYS VAL LYS ILE LYS VAL ARG GLN ALA TRP ARG GLU
HET HEM 395 73
HETNAM HEM PROTOPORPHYRIN IX CONTAINING FE
HETSYN HEM HEME
FORMUL 2 HEM C34 H32 FE N4 O4
HELIX 1 A HIS A 1 TYR A 13 1 13 HELIX 2 B HIS A 31 ILE A 40 1 10 HELIX 3 B' PRO A 50 ASN A 61 1 12 HELIX 4 C GLY A 71 ALA A 83 1 13 HELIX 5 D LEU A 95 HIS A 113 1 19 HELIX 6 E PRO A 123 PHE A 137 1 15 HELIX 7 F PRO A 146 LYS A 164 1 19 HELIX 8 G PRO A 178 LYS A 206 1 29 HELIX 9 H ASN A 214 LEU A 219 1 6 HELIX 10 I ASP A 242 HIS A 273 1 32 HELIX 11 J ASN A 274 VAL A 289 1 16 HELIX 12 J' PRO A 295 ARG A 302 1 8 HELIX 13 K LEU A 303 ARG A 317 1 15 HELIX 14 K' LEU A 349 HIS A 353 1 5 HELIX 15 L GLY A 397 GLN A 414 1 18
SHEET 1 1 5 PRO A 15 MET A 21 0 SHEET 2 1 5 THR A 23 VAL A 29 0 SHEET 3 1 5 GLY A 342 ASN A 348 0 SHEET 4 1 5 PRO A 321 LYS A 327 0 SHEET 5 1 5 LYS A 44 GLY A 48 0 SHEET 1 2 2 ASN A 329 SER A 333 0 SHEET 2 2 2 GLU A 336 ASP A 340 0 SHEET 1 3 3 SER A 117 ILE A 120 0 SHEET 2 3 3 PHE A 442 ARG A 449 0 SHEET 3 3 3 ARG A 415 GLU A 419 0 SHEET 1 4 2 GLY A 431 LYS A 434 0 SHEET 2 4 2 VAL A 436 ASP A 440 0
LINK SG CYS A 395 FE HEM 395
CISPEP 1 ILE A 40 LYS A 41 0 27.84 CISPEP 2 ALA A 83 THR A 84 0 -6.87 CISPEP 3 LYS A 94 LEU A 95 0 -10.22
CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 1.000000 0.000000 0.000000 0.00000
SCALE2 0.000000 1.000000 0.000000 0.00000
SCALE3 0.000000 0.000000 1.000000 0.00000